LatestIP And Trademarks 30 October 2026
Bombay High Court Cancels LEFOXIN BIOX Trademark Over Confusion
The Bombay High Court ordered the removal of the LEFOXIN BIOX trademark after finding it likely to cause confusion with the existing LANOXIN mark, despite the drugs belonging to different therapeutic categories. The court highlighted that both medicines are subject to strict prescription controls and are sold exclusively for export, raising public safety concerns and reinforcing rigorous scrutiny of pharmaceutical trademarks in India.
Bombay High Court has ordered the removal of the LEFOXIN BIOX trademark, ruling it is confusingly similar to the existing LANOXIN mark.
- The two drugs serve different therapeutic areas, but the court emphasized that identical prescription controls and exclusive export‑only sales increase the risk of public confusion.
- The decision underscores strict scrutiny of pharmaceutical trademarks in India.
Read the full judgment here.
Need help understanding this update?
Connect with our domain experts instantly via WhatsApp for customized legal guidance.